<DOC>
	<DOCNO>NCT01986556</DOCNO>
	<brief_summary>This study assess relative bioavailability lesinurad tablet , manufacture two different site .</brief_summary>
	<brief_title>Lesinurad Tablet Relative Bioavailability</brief_title>
	<detailed_description>A change manufacturing site lesinurad tablet implement . This study intend evaluate clinical comparability lesinurad tablet manufacture two different site assess relevant clinical Pharmacokinetics ( PK ) parameter .</detailed_description>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>Subject body weight ≥ 50 kg ( 110 lb ) body mass index ( BMI ) ≥ 18 ≤ 40 kg/m2 . Subject Screening sUA value ≤ 7.0 mg/dL . Subject free clinically significant disease require physician 's care and/or would interfere study evaluation procedure . Subject clinically relevant abnormality vital sign , ECG , physical examination safety laboratory value per Investigator 's judgment . Subject history clinical manifestation significant metabolic , hematological , pulmonary , cardiovascular , gastrointestinal , neurologic , hepatic , renal , urological , psychiatric disorder . Subject history suspicion kidney stone . Subject history asthma . Subject undergone major surgery within 3 month prior Day 1 . Subject donate blood experienced significant blood loss ( &gt; 450 mL ) within 12 week prior Day 1 give plasma donation within 4 week prior Screening visit . Subject inadequate venous access unsuitable vein repeat venipuncture .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>